Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

BACKGROUND: The survival rate for patients with relapsed and refractory acute myeloid leukaemia (R/R-AML) remains poor, and treatment is challenging. Chimeric antigen receptor T cells (CAR-T cells) have been widely used for haematologic malignancies. Current CAR-T therapies for acute myeloid leukaem...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yu, Liu, Ying, Wen, Shupeng, Kuang, Na, Zhang, Xuejun, Li, Jianqiang, Wang, Fuxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753314/
https://www.ncbi.nlm.nih.gov/pubmed/36517851
http://dx.doi.org/10.1186/s12967-022-03797-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753314/
https://www.ncbi.nlm.nih.gov/pubmed/36517851
http://dx.doi.org/10.1186/s12967-022-03797-7

Ejemplares similares